Get the Stockscreener App
52.29
7.48%
3.64
After Hours:
52.36
0.07
+0.13%
Grail Inc stock is traded at $52.29, with a volume of 732.59K.
It is up +7.48% in the last 24 hours and up +0.97% over the past month.
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
See More
Previous Close:
$48.65
Open:
$50.3
24h Volume:
732.59K
Relative Volume:
0.60
Market Cap:
$2.14B
Revenue:
$147.17M
Net Income/Loss:
$-408.35M
P/E Ratio:
-4.6776
EPS:
-11.1787
Net Cash Flow:
$-299.92M
1W Performance:
+8.01%
1M Performance:
+0.97%
6M Performance:
+8.35%
1Y Performance:
+67.60%
1-Day Range:
$49.76
$52.40
1-Week Range:
$45.90
$52.40
52-Week Range:
$20.44
$118.84
Grail Inc Stock (GRAL) Company Profile
Name
Grail Inc
Sector
Industry
Phone
(833) 694-2553
Address
1525 O'BRIEN DRIVE, MENLO PARK
Compare GRAL vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GRAL
Grail Inc
|
52.29 | 2.00B | 147.17M | -408.35M | -299.92M | -11.18 |
TMO
Thermo Fisher Scientific Inc
|
490.77 | 182.14B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
187.15 | 134.43B | 24.57B | 3.60B | 5.26B | 5.051 |
IDXX
Idexx Laboratories Inc
|
575.72 | 45.40B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
112.98 | 32.27B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
302.32 | 29.62B | 3.17B | 642.63M | 516.49M | 10.77 |
Grail Inc Stock (GRAL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-26 | Upgrade | TD Cowen | Hold → Buy |
| Feb-19-26 | Initiated | TD Cowen | Hold |
| Feb-17-26 | Initiated | Robert W. Baird | Outperform |
| Dec-02-25 | Resumed | Morgan Stanley | Equal-Weight |
| Nov-12-25 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-25 | Initiated | Canaccord Genuity | Buy |
| Nov-27-24 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Oct-17-24 | Initiated | Guggenheim | Neutral |
View All
Grail Inc Stock (GRAL) Latest News
Why Grail Stock Is Surging Back With Force - TipRanks
Illumina Inc stock faces headwinds amid Grail divestiture and biotech sector pressures - AD HOC NEWS
Illumina Inc. stock faces ongoing challenges from Grail divestiture and genomics market pressures - AD HOC NEWS
Illumina Inc. stock faces headwinds amid Grail divestiture scrutiny and biotech sector slowdown - AD HOC NEWS
(GRAL) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Guggenheim reiterates Buy rating on Grail stock, cites FDA approval path - Investing.com Canada
Guggenheim reiterates Buy rating on Grail stock, cites FDA approval path By Investing.com - Investing.com South Africa
GRAL Stock Price, Quote & Chart | GRAIL INC (NASDAQ:GRAL) - ChartMill
Hims latest offering, Grail's Galleri cancer test, fails U.K. study - MSN
Illumina Inc. stock faces renewed scrutiny amid Grail divestiture delays and biotech sector headwind - AD HOC NEWS
One Fin Capital Exits GRAIL Position, Sells 380,000 SharesNews and Statistics - IndexBox
This Investor Exited a $22 Million GRAIL Stake Before a 50% One-Day Stock Crash Last Month - The Motley Fool
GRAIL, Inc. Opens with 5.11% Gain, Outperforming S&P 500's 1.01% Rise - Markets Mojo
Here's why Grail shares crushed the market this week - MSN
Grail Stock Upgrade: Analyst Sees Buy Opportunity Despite Trial DataNews and Statistics - IndexBox
Here's Why Grail Shares Crushed the Market This Week - AOL.com
GRAIL Upgraded to Buy at TD Cowen - National Today
Grail’s Cancer Detection Test Fails in Major Study — What It Means for the Future of Early Cancer Screening - vocal.media
Grail Inc’s Earnings Call Balances Momentum and Risk - TipRanks
Levi & Korsinsky, LLP: Grail (GRAL) Guided to 2030 Cash Runway While Key Trial Risk Went Unaddressed - GlobeNewswire
The Escalator: Biogen, Flagship Pioneering, Grail and more - Medical Marketing and Media
GRAIL announces leadership transition - MSN
Archaeopteryx | The Holy Grail of Fossils at the Field Museum - Britannica
Grail stock jumps after TD Cowen upgrade on cancer test outlook - Investing.com Canada
Grail slides as trial misses primary endpoint, fails to show significant stage III-IV cancer reduction - MSN
GRAIL outlines 2025 commercial growth plans and targets up to 30% US Galleri revenue increase - MSN
Grail stock jumps after TD Cowen upgrade on cancer test outlook By Investing.com - Investing.com Australia
Grail stock upgraded at TD Cowen after selloff (GRAL:NASDAQ) - Seeking Alpha
GRAIL (NASDAQ:GRAL) Trading Up 6.9% Following Analyst Upgrade - MarketBeat
Here’s what analysts are saying about Grail Inc. (GRAL) - MSN
LEVI & KORSINSKY, LLP: GRAIL (GRAL) GUIDED TO 2030 CASH RUNWAY WHILE KEY TRIAL RISK WENT UNADDRESSED - marketscreener.com
GRAIL (NASDAQ:GRAL) Raised to Buy at TD Cowen - MarketBeat
TD Cowen upgrades Grail stock rating to buy on cancer detection market potential - Investing.com Australia
TD Cowen upgrades Grail stock rating to buy on cancer detection market potential By Investing.com - Investing.com South Africa
TD Cowen Upgrades GRAIL to Buy From Hold, Adjusts Price Target to $65 From $114 - marketscreener.com
GRAL Technical Analysis | Trend, Signals & Chart Patterns | GRAIL INC (NASDAQ:GRAL) - ChartMill
GRAIL, Inc. (NASDAQ:GRAL) Sees Significant Increase in Short Interest - MarketBeat
Does GRAIL (GRAL) Elevating Josh Ofman to CEO Reframe Its Management Quality Narrative? - simplywall.st
GRAIL names Josh Ofman as CEO, Bob Ragusa to retire June 1 - Investing.com Nigeria
Grail CEO Bob Ragusa to retire - MedTech Dive
Farallon Capital Management LLC Buys 847,000 Shares of GRAIL, Inc. $GRAL - MarketBeat
GRAIL, Inc. (NASDAQ:GRAL) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
GRAIL2026 Funding Rounds & List of Investors - Tracxn
Assessing GRAIL (GRAL) Valuation After Recent Share Price Pullback And Ongoing Growth Challenges - Yahoo Finance
Canaccord Genuity Reaffirms Their Buy Rating on GRAIL Inc (GRAL) - The Globe and Mail
Guggenheim Sticks to Their Buy Rating for GRAIL Inc (GRAL) - The Globe and Mail
GRAIL Inc (GRAL) Shares Down 4.59% on Mar 13 - GuruFocus
Assessing GRAIL (GRAL) Valuation After Recent Share Price Volatility and Narrative Fair Value Gap - simplywall.st
Grail Inc. Announces CEO Transition - Contract Pharma
Grail CEO to retire after failed cancer detection trialSan Francisco Business Times - The Business Journals
Grail Inc Stock (GRAL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.19%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):